Sandu Pharmaceuticals Falls to 52-Week Low of Rs.38 Amidst Continued Downtrend

On 18 Nov 2025, Sandu Pharmaceuticals touched Rs.38, its lowest price in the past year, continuing a losing streak that spans two consecutive trading sessions. Over these two days, the stock has recorded a cumulative return of -3.49%, with a day change of -1.94% on the latest session. This performance trails the Pharmaceuticals & Biotechnology sector by approximately -1.76% on the same day, indicating relative weakness within its industry group.

Technical indicators show that Sandu Pharmaceuticals is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This broad-based decline across short, medium, and long-term moving averages suggests sustained selling pressure and a lack of upward momentum in the stock price.

The broader market context reveals a mixed environment. The Sensex opened positively, gaining 91.42 points, but subsequently declined by -186.35 points to close at 84,856.02, down -0.11%. Despite this minor setback, the Sensex remains close to its 52-week high of 85,290.06, just 0.51% away, and is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, signalling an overall bullish trend for the benchmark index. In contrast, Sandu Pharmaceuticals’ performance diverges notably from this broader market strength.

Examining the one-year performance, Sandu Pharmaceuticals has recorded a return of -26.70%, a stark contrast to the Sensex’s positive return of 9.72% over the same period. This underperformance extends beyond the last year, as the stock has consistently lagged behind the BSE500 index in each of the past three annual periods. The stock’s 52-week high was Rs.62.8, highlighting the extent of the decline to its current low.

From a fundamental perspective, Sandu Pharmaceuticals exhibits several areas of concern. The company’s average Return on Equity (ROE) over the long term stands at 3.73%, which is relatively modest and points to limited profitability in relation to shareholder equity. Net sales have grown at an annual rate of 4.69% over the last five years, while operating profit has shown a rate of 17.92% during the same timeframe. These figures suggest subdued growth compared to more dynamic peers in the Pharmaceuticals & Biotechnology sector.

Debt servicing capacity also appears constrained, with an average EBIT to interest ratio of 1.92. This ratio indicates the company’s earnings before interest and tax are less than twice its interest obligations, reflecting a cautious stance on financial leverage and coverage. The quarterly net sales figure reported recently was Rs.14.07 crores, marking the lowest quarterly sales level observed, which may contribute to the stock’s subdued market sentiment.

Valuation metrics provide a mixed picture. The stock trades at a Price to Book Value of approximately 1, suggesting a fair valuation relative to its book value. This valuation aligns with the company’s peer group average historical valuations, indicating that the market is pricing Sandu Pharmaceuticals in line with its sector counterparts. Despite the negative stock return over the past year, the company’s profits have risen by 10.9%, resulting in a Price/Earnings to Growth (PEG) ratio of 2.4. This ratio reflects the relationship between the company’s valuation, earnings, and growth prospects.

Ownership structure reveals that the majority shareholders are non-institutional investors, which may influence trading patterns and liquidity characteristics. The company’s market capitalisation grade is rated at 4, reflecting its relative size and market presence within the Pharmaceuticals & Biotechnology sector.

In summary, Sandu Pharmaceuticals’ recent fall to a 52-week low of Rs.38 is underpinned by a combination of subdued financial metrics, consistent underperformance relative to benchmarks, and technical indicators signalling continued weakness. While the broader market and sector indices maintain more positive trends, Sandu Pharmaceuticals remains on a downward trajectory, with valuation and profitability metrics reflecting a cautious outlook.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →